Tr1X

Tr1X develops innovative regulatory T cell-based therapies aimed at curing autoimmune and inflammatory diseases. Targeted towards patients suffering from conditions with significant unmet medical needs, Tr1X stands out as the first company to utilize allogeneic engineered Tr1 cell therapy in clinical trials, positioning itself as a pioneer in this promising area of biotechnology.